PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media288616ArticlesСтатьиResearch ArticleNSAID-INDUCED GASTROPATHIES: PATHOGENETICALLY SUBSTANTIATED APPROACHES TO PREVENTION AND THERAPYГАСТРОПАТИИ, ИНДУЦИРОВАННЫЕ НЕСТЕРОИДНЫМИ ПРОТИВОВОСПАЛИТЕЛЬНЫМИ СРЕДСТВАМИ: ПАТОГЕНЕТИЧЕСКИ ОБОСНОВАННЫЕ ПОДХОДЫ К ПРОФИЛАКТИКЕ И ТЕРАПИИMaevI. VМаевИ. ВAndreevD. NАндреевД. Н

Teaching Assistant of the Department of Propedeutics of Internal Diseases and Gastroenterology

ассистент кафедры пропедевтики внутренних болезней и гастроэнтерологии

dna-mit8@mail.ruDichevaD. TДичеваД. ТSBEI HPE MSMSU n.a. A.I. Evdokimov of RMPHГБОУ ВПО МГМСУ им. А.И. Евдокимова Минздрава России20012016232NO2 (2016)№2 (2016)495426022023Copyright ©; 2016, Bionika MediaCopyright ©; 2016, ООО «Бионика Медиа»2016Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/288616

Non-steroidal anti-inflammatory drug-induced gastropathy (NSAID-gastropathy) often occurs in clinical practice due to wide use of this group of drugs. Currently, the most common of the therapeutic strategies applied considered are combination of NSAIDs with proton pump inhibitors, and the use of selective cyclooxygenase-2 inhibitors. The introduction of the new drug with proven effect, rebamipide, having a gastroprotective action by increasing the production of endogenous prostaglandins, opens up new prospects for management of this difficult group of patients in clinical practice.

Гастропатии, индуцированные нестероидными противовоспалительными средствами (НПВС-гастропатии), встречаются в клинической практике ввиду широкого применения этой группы препаратов. На данный момент наиболее распространенной из применяемых терапевтических стратегий считается комбинация НПВС с ингибиторами протонной помпы, а также применение селективных ингибиторов циклооксигеназы-2. Внедрение в клиническую практику нового препарата с доказанным эффектом, ребамипида, обладающего гастропротективным действием за счет повышения продукции эндогенных простагландинов, открывает новые перспективы ведения этой непростой группы пациентов.

non-steroidal anti-inflammatory drugsNSAID-gastropathyprostaglandinscyclooxygenaseproton pump inhibitorsgastroprotectivesнестероидные противовоспалительные средстваНПВС-гастропатияпростагландиныциклооксигеназаингибиторы протонной помпыгастропротекторыRoth S.H. Nonsteroidal anti-inflammatory drug gastropathy. We started it--can we stop it? Arch. Intern. Med. 1986;146(6):1075-76.Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М., 2015.Lewis S.C., Langman M.J., Laporte J.R., Matthews J.N., Rawlins M.D., Wiholm B.E. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br. J. Clin. Pharmacol. 2002;54(3):320-26.DeRuiter J. Non-steroidal antiinflammatory drugs (NSAIDS) Principles of Drug Action. 2002;2:1-25.Sostres C., Gargallo C.J., Arroyo M. T., Lanas A. Adverse effects of non-steroidal anti-nflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract. & Res. Clin. Gastroenterol. 2010;24:121-32.Zidar N., Odar K., Glavac D., Jerse M., Zupanc T., Stajer D. Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? Cellular and Molecular Medicine B. 2009;13(9):3753-63.Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointestinal Endoscopy Clinics of North America. 1996;6(3):489-504.Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(24):11693-97.Gudis K., Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Digestive Diseases and Sciences. 2005;50(1): 16-23.Konturek S.J., Konturek P.C., Pawlik T., Sliwownski Z., Ochmanski W., Hahn E.G. Duodenal mucosal protection by bicarbonate secretion and its mechanisms. J. Physiol. Pharmacol. 2004;55:5-17.Свинцицкий А.С. НПВС-гастродуоденопатии у больных остеоартрозом: особенности диагностики, профилактики и лечения. Научно-практическая ревматология. 2002;3:26-31.Hudson N., Balsitis M., Everitt S., Hawkey C.J. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993;34(6):742-47.Vaananen P.M., Keenan C.M., Grisham M.B., Wallace J.L. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation. 1992; 16(3):22 7-40.Andrews F.J., Malcontenti-Wilson C., O'Brien P.E. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. Am. J. Physiol. 1994;266(4, part. 1):657-64.McCafferty D.M., Granger D.N., Wallace J.L. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology. 1995; 109(4): 11 73-80.Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов (часть I). Клин. мед. 2000;3:4-9.Fiorucci S., Antonelli E., Morelli A. Mechanism of non-steroidal anti-infammatory drug-gastropathy. Digest Liver Dis. 2001;33(Suppl. 2):S35.Santucci L., Fiorucci S., Giansanti M., Brunori P.M., Di Matteo F.M., Morelli A. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. Gut. 1994;35(7):909-15.Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М., 2016.Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-infl ammatory drugs in pepticulcer disease: a meta-analysis. Lancet. 2002; 359(9300):14-22.Lim Y.J., Hong S.J. Helicobacter pylori infection in nonsteroidal anti-infl ammatory drug users. Korean J. Gastroenterol. 2014;64(2):70-5.Lanza F.L., Chan F.K., Quigley E.M. Practice Parameters Committee of the American College of Gastroenterology, Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterology. 2009; 104(3):728-38.Каратеев А.Е. Что лучше для профилактики НПВС-гастропатии: коксибы или комбинация «традиционных» НПВС и гастропротектора? РМЖ. 2013;13:673-80.Laine L. The role of proton pump inhibitors in NSAID - associated gastropathy and upper gastrointestinal symptoms. Reviews in Gastroenterological Disorders. 2003;3(4):30-9.Micklewright R., Lane S., Linley W., McQuade C., Thompson F., Maskrey N. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Alimentary Pharmacology and Therapeutics. 2003;17(3):321-32.Patrignani P., Tacconelli S., Capone M.L. Risk management profile of etoricoxib: an example of personalized medicine. Therapeutics and Clinical Risk Management. 2008;4(5):983-97.Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B., Villiger P.M., Egger M., Jüni P. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011 ;342:7086.Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000;343(21 ): 1520-28.Schwartz J., Dallob A., Larson P., Laterza O.F., Miller J., Royalty J., Snyder K.M., Chappell D.L., Hilliard D.A., Flynn M.E., Cavanaugh P.F. Jr, Wagner J.A. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J. Clin. Pharmacol. 2008;48(6):745-54.Chan F., Lanas A., Scheiman J., Berger M.F., Nguyen H., Goldstein J.L. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;3 76:173- 79.Goldstein J., Eisen G., Lewis B., Gralnek I.M., Zlotnick S., Fort J.G. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin. Gastroenterol. Hepatol. 2005;3-13.Mattia C., Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anesthesiology. 2005;71(7-8):461-70.Nguyen A., Chaiton A. Cyclooxygenase (COX-2) selective inhibitors: any better than NSAIDs? Canadian Family Physician. 2001;47: 1398-400.Bhala N., Emberson J., Merhi A., et al. Vascular and upper gastrointestinal effects of non-steroidal antiinflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-79.Bell N.J., Hunt R.H. Progress with proton pump inhibition. Yale J. Biol. Med. 1992;65(6): 649-57.Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs -nice or necessary? Rev. Gastroenterol. Dis. 2004;4(Suppl. 4):33-41.Malfertheiner P., Megraud F., O'Morain C., Atherton J., Axon A.T., Bazzoli F., Gensini G.F., Gisbert J.P., Graham D.Y., Rokkas T., El-Omar E.M., Kuipers E.J. Management of Helicobacter pylori infection - Maastricht IV. Florence Consensus Report. Gut. 2012;61:646-64.Vergara M., Catalan M., Gisbert J.P., Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol. Ther. 2 005;21:1411e18.Koch M. Non-steroidal anti-inflammatory drug gastropathy: clinical results with misoprostol. Italian J. Gastroenterol. Hepatol. 1999; 31(1):54-62.Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Int. Med. 1995; 123 (4):241 -49.Graham Y., White R.H., Moreland L.W., et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann. Int. Med. 1993;119(4):257-62.Iinuma S., Naito Y., Yoshikawa T., Takahashi S., Takemura T., Yoshida N., Kondo M. In vitro studies indicating antioxidative properties of rebamipide. Dig. Dis. Sci. 1998; 43(Suppl. 9):35-9.Yoshida N., Yoshikawa T., Iinuma S., Arai M., Takenaka S., Sakamoto K., Miyajima T., Nakamura Y., Yagi N., Naito Y., Mukai F., Kondo M. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig. Dis. Sci. 1996;41(6):1139-44.Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev. Gastroenterol. Hepatol. 2010;4(3):261-70.Zhang S., Qing Q., Bai Y., Mao H., Zhu W., Chen Q., Zhang Y., Chen Y. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and metaanalysis. Dig. Dis. Sci. 2013;58(7):1991-2000.Kim J.H., Park S.H., Cho C.S., Lee S.T., Yoo W.H., Kim S.K., Kang Y.M., Rew J.S., Park Y.W., Lee S.K., Lee Y.C., Park W., Lee D.H. Preventive efficacy and safety of rebamipid in NSAD-indused toxicity. Gut. Liver. 2014;8(4):371-79.Park S.H., Cho C.S., Lee O.Y., et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. J. Clin. Biochem. Nutr. 200; 40(2):148-55.Tozawa K., Oshima T., Okugawa T., Ogawa T., Ohda Y., Tomita T., Hida N., Fukui H., Hori K., Watari J., Nakamura S., Miwa H. A Randomized, Double-Blind, Placebo-Controlled Study of Rebamipide for Gastric Mucosal Injury Taking Aspirin With or Without Clopidogrel. Dig. Dis. Sci. 2014;59(8): 1885-90.